Literature DB >> 28344320

DPP4 truncated GM-CSF and IL-3 manifest distinct receptor-binding and regulatory functions compared with their full-length forms.

H A O'Leary1,2, M Capitano1, S Cooper1, C Mantel1, H S Boswell2, R Kapur3, B Ramdas3, R Chan3,4, L Deng4, C-K Qu5, H E Broxmeyer1.   

Abstract

Dipeptidylpeptidase 4 (DPP4/CD26) enzymatically cleaves select penultimate amino acids of proteins, including colony-stimulating factors (CSFs), and has been implicated in cellular regulation. To better understand the role of DPP4 regulation of hematopoiesis, we analyzed the activity of DPP4 on the surface of immature blood cells and then comparatively assessed the interactions and functional effects of full-length (FL) and DPP4 truncated (T) factors (T-granulocyte-macrophage-CSF (T-GM-CSF)) and T-interleukin-3 (T-IL-3)) on both in vitro and in vivo models of normal and leukemic cells. T-GM-CSF and -IL-3 had enhanced receptor binding, but decreased CSF activity, compared with their FL forms. Importantly, T-GM-CSF and -IL-3 significantly, and reciprocally, blunted receptor binding and myeloid progenitor cell proliferation activity of both FL-GM-CSF and -IL-3 in vitro and in vivo. Similar effects were apparent in vitro using cluster-forming cells from patients with acute myeloid leukemia regardless of cytogenetic or molecular alterations and in vivo using animal models of leukemia. This suggests that DPP4 T-molecules have modified binding and functions compared with their FL counterparts and may serve regulatory roles in normal and malignant hematopoiesis.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28344320      PMCID: PMC5650952          DOI: 10.1038/leu.2017.98

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  35 in total

Review 1.  Hematopoiesis: a human perspective.

Authors:  Sergei Doulatov; Faiyaz Notta; Elisa Laurenti; John E Dick
Journal:  Cell Stem Cell       Date:  2012-02-03       Impact factor: 24.633

2.  Hematopoietic stem/progenitor cells, generation of induced pluripotent stem cells, and isolation of endothelial progenitors from 21- to 23.5-year cryopreserved cord blood.

Authors:  Hal E Broxmeyer; Man-Ryul Lee; Giao Hangoc; Scott Cooper; Nutan Prasain; Young-June Kim; Coleen Mallett; Zhaohui Ye; Scott Witting; Kenneth Cornetta; Linzhao Cheng; Mervin C Yoder
Journal:  Blood       Date:  2011-03-10       Impact factor: 22.113

3.  Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1 alpha-mediated chemotaxis of human cord blood CD34+ progenitor cells.

Authors:  Kent W Christopherson; Giao Hangoc; Hal E Broxmeyer
Journal:  J Immunol       Date:  2002-12-15       Impact factor: 5.422

4.  Evidence for a proliferative advantage of human leukemia colony-forming cells in vitro.

Authors:  H E Broxmeyer; E Grossbard; N Jacobsen; M A Moore
Journal:  J Natl Cancer Inst       Date:  1978-03       Impact factor: 13.506

5.  Implication of Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Interleukin-3 (IL-3) in Children with Acute Myeloid Leukaemia (AML); Malignancy.

Authors:  Osama Elbaz; Ali Shaltout
Journal:  Hematology       Date:  2001       Impact factor: 2.269

6.  Modulation of hematopoietic stem cell homing and engraftment by CD26.

Authors:  Kent W Christopherson; Giao Hangoc; Charlie R Mantel; Hal E Broxmeyer
Journal:  Science       Date:  2004-08-13       Impact factor: 47.728

Review 7.  The role of dipeptidyl peptidase 4 in hematopoiesis and transplantation.

Authors:  Heather O'Leary; Xuan Ou; Hal E Broxmeyer
Journal:  Curr Opin Hematol       Date:  2013-07       Impact factor: 3.284

8.  Interleukin (IL)-3/granulocyte macrophage-colony stimulating factor/IL-5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemias with mutated FMS-related tyrosine kinase 3 receptor.

Authors:  Roberta Riccioni; Daniela Diverio; Viviana Riti; Sonia Buffolino; Gualtiero Mariani; Alessandra Boe; Michele Cedrone; Tiziana Ottone; Robin Foà; Ugo Testa
Journal:  Br J Haematol       Date:  2008-11-13       Impact factor: 6.998

Review 9.  Implications of DPP4 modification of proteins that regulate stem/progenitor and more mature cell types.

Authors:  Xuan Ou; Heather A O'Leary; Hal E Broxmeyer
Journal:  Blood       Date:  2013-05-01       Impact factor: 22.113

10.  FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia.

Authors:  Benjamin H Lee; Zuzana Tothova; Ross L Levine; Kristina Anderson; Natalija Buza-Vidas; Dana E Cullen; Elizabeth P McDowell; Jennifer Adelsperger; Stefan Fröhling; Brian J P Huntly; Miloslav Beran; Sten Eirik Jacobsen; D Gary Gilliland
Journal:  Cancer Cell       Date:  2007-10       Impact factor: 31.743

View more
  5 in total

1.  Open the gates: vascular neurocrine signaling mobilizes hematopoietic stem and progenitor cells.

Authors:  Tomer Itkin; Jesús María Gómez-Salinero; Shahin Rafii
Journal:  J Clin Invest       Date:  2017-11-13       Impact factor: 14.808

2.  Leukemia Inhibitory Factor Promotes Survival of Hematopoietic Progenitors Ex Vivo and Is Post-Translationally Regulated by DPP4.

Authors:  James Ropa; Scott Cooper; Hal E Broxmeyer
Journal:  Stem Cells       Date:  2022-03-31       Impact factor: 5.845

3.  Cooperating, congenital neutropenia-associated Csf3r and Runx1 mutations activate pro-inflammatory signaling and inhibit myeloid differentiation of mouse HSPCs.

Authors:  Malte Ritter; Maksim Klimiankou; Olga Klimenkova; Axel Schambach; Dirk Hoffmann; Amy Schmidt; Lothar Kanz; Daniel C Link; Karl Welte; Julia Skokowa
Journal:  Ann Hematol       Date:  2020-08-03       Impact factor: 3.673

Review 4.  An expanded role for dipeptidyl peptidase 4 in cell regulation.

Authors:  James Ropa; Hal E Broxmeyer
Journal:  Curr Opin Hematol       Date:  2020-07       Impact factor: 3.218

Review 5.  Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions.

Authors:  Shiying Shao; QinQin Xu; Xuefeng Yu; Ruping Pan; Yong Chen
Journal:  Pharmacol Ther       Date:  2020-02-14       Impact factor: 12.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.